The effect of n-3 polyunsaturated fatty acids on leukotriene B4 and leukotriene B5 production from stimulated neutrophil granulocytes in patients with chronic kidney disease

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 1, 2011, Pages 37-41

  Maaloe T ^a   Schmidt, E B ^a   Svensson, M ^b   Aardestrup, I V ^a   Christensen, J H ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chronic kidney disease; Double blind randomized trial; Leukotrienes; N 3 fatty acids

Indexed keywords

5 HYDROXYICOSAPENTAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; FISH OIL; HYDROXY FATTY ACID; LEUKOTRIENE B4; LEUKOTRIENE B5; OLIVE OIL; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATTY ACID SYNTHESIS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DOWN-REGULATION; EICOSAPENTAENOIC ACID; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; GRANULOCYTES; HUMANS; KIDNEY; LEUKOTRIENE B4; MALE; MIDDLE AGED; NEUTROPHIL ACTIVATION; NEUTROPHILS; PATIENT DROPOUTS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 79957710288     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.04.004     Document Type: Article

References (36)

1. Ayodele O.E., Alebiosu C.O. Burden of chronic kidney disease: an international perspective. Adv. Chronic Kidney Dis. 2010, 17:215-224.
2. Lysaght M.J. Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. Nephrol. 2002, 13(Suppl. 1):S37-S40.
3. Fassett R.G., Gobe G.C., Peake J.M., Coombes J.S. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am. J. Kidney Dis. 2010, 56:728-742.
4. Pestka J.J. n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82:251-258.
5. Tonelli M., Sacks F., Pfeffer M., Jhangri G.S., Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005, 68:237-245.
6. Rodriguez-Iturbe B., Garcia G.G. The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin. Pract. 2010, 116:c81-c88.
7. Donadio J.V. n-3 Fatty acids and their role in nephrologic practice. Curr. Opin. Nephrol. Hypertens. 2001, 10:639-642.
8. Lauretani F., Maggio M., Pizzarelli F., et al. Omega-3 and renal function in older adults. Curr. Pharm. Des. 2009, 15:4149-4156.
9. Calder P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 2006, 83:1505S-1519S.
10. Goodnow R.A., Hicks A., Sidduri A., et al. Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1. J. Med. Chem. 2010, 53:3502-3516.
11. Badr K.F. Five-lipoxygenase products in glomerular immune injury. J. Am. Soc. Nephrol. 1992, 3:907-915.
12. Robinson J.G., Stone N.J. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am. J. Cardiol. 2006, 98:39i-49i.
13. Lee T.H., Menica-Huerta J.M., Shih C., Corey E.J., Lewis R.A., Austen K.F. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J. Biol. Chem. 1984, 259:2383-2389.
14. Goldman D.W., Pickett W.C., Goetzl E.J. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem. Biophys. Res. Commun. 1983, 117:282-288.
15. Noiri E., Yokomizo T., Nakao A., et al. An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury. Proc. Natl. Acad. Sci. USA 2000, 97:823-828.
16. Spurney R.F., Ruiz P., Albrightson C.R., Pisetsky D.S., Coffman T.M. Fish oil feeding modulates leukotriene production in murine lupus nephritis. Prostaglandins 1994, 48:331-348.
17. Yared A., Albrightson-Winslow C., Griswold D., Takahashi K., Fogo A., Badr K.F. Functional significance of leukotriene B4 in normal and glomerulonephritic kidneys. J. Am. Soc. Nephrol. 1991, 2:45-56.
18. Nakao A., Nosaka K., Ohishi N., et al. Long-term effects of LTB4 antagonist on lipid induced renal injury. Kidney Int. Suppl. 1997, 63:S236-S238.
19. Suzuki S., Kuroda T., Kazama J.I., et al. The leukotriene B4 receptor antagonist ONO-4057 inhibits nephrotoxic serum nephritis in WKY rats. J. Am. Soc. Nephrol. 1999, 10:264-270.
20. Taccone-Gallucci M., Manca-di-Villahermosa S., Battistini L., Stuffler R.G., Tedesco M., Maccarrone M. N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. Kidney Int. 2006, 69:1450-1454.
21. Wu S.H., Liao P.Y., Yin P.L., Zhang Y.M., Dong L. Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am. J. Pathol. 2009, 174:115-122.
22. Wall R., Ross R.P., Fitzgerald G.F., Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr. Rev. 2010, 68:280-289.
23. Clark W.F., Parbtani A., Huff M.W., Reid B., Holub B.J., Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int. 1989, 36:653-660.
24. Mickleborough T.D., Lindley M.R., Ionescu A.A., Fly A.D. Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest 2006, 129:39-49.
25. Lossl K., Skou H.A., Christensen J.H., Schmidt E.B. The effect of n-3 fatty acids on leukotriene formation from neutrophils in patients on hemodialysis. Lipids 1999, 34(Suppl.). S185.
26. Panchaud A., Sauty A., Kernen Y., et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin. Nutr. 2006, 25:418-427.
27. Svensson M., Christensen J.H., Solling J., Schmidt E.B. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. Am. J. Kidney Dis. 2004, 44:77-83.
28. Varming K., Schmidt E.B., Svaneborg N., et al. The effect of n-3 fatty acids on neutrophil chemiluminescence. Scand. J. Clin. Lab. Invest. 1995, 55:47-52.
29. Ferrante A., Thong Y.H. A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique. J. Immunol. Methods 1978, 24:389-393.
30. Vogt J., Andersen V.L., Andreasen A., Obel T., Christensen J.H., Schmidt E.B. Serum concentrations of matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1 and alpha2-macroglobulin in healthy subjects after supplementation with different doses of marine n-3 fatty acids. Cell. Mol. Biol. (Noisy-le-grand) 2010, 56:102-109.
31. Hwang D.H., Boudreau M., Chanmugam P. Dietary linolenic acid and longer-chain n-3 fatty acids: comparison of effects on arachidonic acid metabolism in rats. J. Nutr. 1988, 118:427-437.
32. Grimminger F., Durr U., Seeger W. Ligand-operated synthesis of 4-series and 5-series leukotrienes in human neutrophils: critical dependence on exogenous free fatty acid supply. Mol. Pharmacol. 1992, 41:757-766.
33. Powell W.S., Gravel S., Gravelle F Formation of a 5-oxo metabolite of 5,8,11,14,17-eicosapentaenoic acid and its effects on human neutrophils and eosinophils. J. Lipid Res. 1995, 36:2590-2598.
34. Friedman A.N. Omega-3 fatty acid supplementation in advanced kidney disease. Semin. Dial. 2010, 23:396-400.
35. Vanholder R., Massy Z., Argiles A., Spasovski G., Verbeke F., Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 2005, 20:1048-1056.
36. Svensson M., Schmidt E.B., Jorgensen K.A., Christensen J.H. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin. J. Am. Soc. Nephrol. 2006, 1:780-786.